Leerink Partners

Leerink Partners Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Leerink Partners. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leerink Partners' equity research team. MarketBeat is not affiliated with or endorsed by Leerink Partners.

Average Return
00.00% 12-Month ROI
Total Ratings
432 Last 12 Months
Buy Ratings
303 Last 12 Months
Sell Ratings
2 Last 12 Months
Companies Covered
244 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
0 Results
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Erasca, Inc. stock logo
ERAS
Erasca
$13.66
-1.7%
11/17/2026 Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Erasca (NASDAQ:ERAS) on 11/17/2026
Viatris Inc. stock logo
VTRS
Viatris
$20.33
-0.6%
11/17/2026Boost Price Target$22.00 ➝ $24.00OutperformView details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 11/17/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$8.24
+1.1%
11/16/2026Boost Price Target$18.00 ➝ $18.27OutperformView details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 11/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$145.80
+1.0%
11/16/2026Initiated Coverage$228.00OutperformView details for Leerink Partners rating of Palvella Therapeutics (NASDAQ:PVLA) on 11/16/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$156.94
-0.5%
11/13/2026Boost Price Target$185.00 ➝ $215.00OutperformView details for Leerink Partners rating of Belite Bio (NASDAQ:BLTE) on 11/13/2026
enGene Holdings Inc. stock logo
ENGN
enGene
$1.81
+4.9%
11/13/2026Upgrade$5.00Market Perform ➝ OutperformView details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 11/13/2026
KARD
Kardigan
$12.68
-3.9%
11/13/2026Lower Price Target$37.00 ➝ $36.00OutperformView details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 11/13/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$8.19
-0.1%
11/13/2026Downgrade$7.00Outperform ➝ Market PerformView details for Leerink Partners rating of NeuroPace (NASDAQ:NPCE) on 11/13/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$115.77
+3.4%
11/13/2026Lower Price Target$190.00 ➝ $175.00OutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 11/13/2026
Veradermics, Incorporated stock logo
MANE
Veradermics
$124.37
-1.0%
11/9/2026Boost Price Target$135.00 ➝ $150.00OutperformView details for Leerink Partners rating of Veradermics (NYSE:MANE) on 11/9/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$95.73
-0.3%
11/6/2026Downgrade$110.00 ➝ $117.00Outperform ➝ HoldView details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 11/6/2026
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$7.29
-3.3%
11/5/2026Boost Price Target$7.00 ➝ $8.00OutperformView details for Leerink Partners rating of AdaptHealth (NASDAQ:AHCO) on 11/5/2026
Amgen Inc. stock logo
AMGN
Amgen
$444.13
-3.0%
11/5/2026Boost Price Target$395.00 ➝ $464.00Market PerformView details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.79
+3.2%
11/5/2026Boost Price Target$23.00 ➝ $25.00OutperformView details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 11/5/2026
Bruker Corporation stock logo
BRKR
Bruker
$63.12
+2.9%
11/5/2026Boost Price Target$80.00 ➝ $85.00OutperformView details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 11/5/2026
Cencora, Inc. stock logo
COR
Cencora
$347.61
-0.8%
11/5/2026Boost Price Target$388.00 ➝ $405.00OutperformView details for Leerink Partners rating of Cencora (NYSE:COR) on 11/5/2026
CVS Health Corporation stock logo
CVS
CVS Health
$81.34
-5.2%
11/5/2026Lower Price Target$112.00 ➝ $104.00OutperformView details for Leerink Partners rating of CVS Health (NYSE:CVS) on 11/5/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$51.53
-0.2%
11/5/2026Lower Price Target$103.00 ➝ $100.00OutperformView details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 11/5/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$105.34
-0.1%
11/5/2026Boost Price Target$101.00 ➝ $112.00OutperformView details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 11/5/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$68.46
-0.1%
11/5/2026Boost Price Target$55.00 ➝ $58.00Market PerformView details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 11/5/2026
Incyte Corporation stock logo
INCY
Incyte
$118.24
-0.7%
11/5/2026Lower Price Target$154.00 ➝ $150.00OutperformView details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 11/5/2026
McKesson Corporation stock logo
MCK
McKesson
$1,081.70
-0.9%
11/5/2026Boost Price Target$1,070.00 ➝ $1,200.00OutperformView details for Leerink Partners rating of McKesson (NYSE:MCK) on 11/5/2026
Medline stock logo
MDLN
Medline
$39.04
+3.6%
11/5/2026Boost Price Target$43.00 ➝ $46.00OutperformView details for Leerink Partners rating of Medline (NASDAQ:MDLN) on 11/5/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$92.26
+0.3%
11/5/2026Lower Price Target$154.00 ➝ $140.00OutperformView details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 11/5/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.62
+1.4%
11/5/2026Boost Price Target$5.00 ➝ $8.00Market PerformView details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 11/5/2026
Progyny, Inc. stock logo
PGNY
Progyny
$36.05
-1.8%
11/5/2026Boost Price Target$37.00 ➝ $38.00OutperformView details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 11/5/2026
Insulet Corporation stock logo
PODD
Insulet
$140.09
-3.6%
11/5/2026Boost Price Target$143.00 ➝ $167.00Market PerformView details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 11/5/2026
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$25.17
+5.9%
11/5/2026Boost Price Target$20.00 ➝ $22.00Market PerformView details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 11/5/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$15.91
-2.9%
11/5/2026Boost Price Target$46.00 ➝ $49.00OutperformView details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 11/5/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$42.15
-1.1%
11/5/2026Boost Price Target$45.00 ➝ $52.00OutperformView details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 11/5/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$50.10
-2.0%
11/5/2026Lower Price Target$78.00 ➝ $67.00OutperformView details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 11/5/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$25.37
+4.7%
11/5/2026Downgrade$55.00 ➝ $35.00Outperform ➝ Market PerformView details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$30.17
+0.3%
11/5/2026Boost Price Target$50.00 ➝ $54.00OutperformView details for Leerink Partners rating of Viridian Therapeutics (NASDAQ:VRDN) on 11/5/2026
Retension Pharmaceuticals, Inc. stock logo
RTSN
Retension Pharmaceuticals
$13.69
+20.0%
11/3/2026 Initiated CoverageStrong-BuyView details for Leerink Partners rating of Retension Pharmaceuticals (NASDAQ:RTSN) on 11/3/2026
AbbVie Inc. stock logo
ABBV
AbbVie
$286.36
-2.2%
11/2/2026Boost Price Target$309.00 ➝ $342.00OutperformView details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 11/2/2026
BrightSpring Health Services, Inc. stock logo
BTSG
BrightSpring Health Services
$68.53
-1.9%
11/2/2026Boost Price Target$72.00 ➝ $92.00OutperformView details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 11/2/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$945.29
-1.3%
11/2/2026Boost Price Target$835.00 ➝ $997.00Market PerformView details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 11/2/2026
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$269.62
-4.4%
11/2/2026Boost Price Target$309.00 ➝ $342.00OutperformView details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 11/2/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
$56.87
+2.7%
10/29/2026Boost Price Target$52.00 ➝ $56.00OutperformView details for Leerink Partners rating of AxoGen (NASDAQ:AXGN) on 10/29/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$43.68
+1.5%
10/29/2026Lower Price Target$55.00 ➝ $50.00OutperformView details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/29/2026
A Bill Would Reprice America's Gold at Market Value (Ad)

The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel

Request your free 2026 Gold Guide to see what repricing could mean for you.
Replimune Group, Inc. stock logo
REPL
Replimune Group
$19.71
+0.1%
10/29/2026Boost Price Target$19.00 ➝ $31.00OutperformView details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 10/29/2026
Labcorp Holdings Inc. stock logo
LH
Labcorp
$370.18
+0.5%
10/28/2026Set Price Target$410.00View details for Leerink Partners rating of Labcorp (NYSE:LH) on 10/28/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$2.79
-1.9%
10/27/2026 Set Price Target$10.00View details for Leerink Partners rating of WAVE Life Sciences (NASDAQ:WVE) on 10/27/2026
DexCom, Inc. stock logo
DXCM
DexCom
$82.49
+0.5%
10/26/2026 Lower Price Target$94.00 ➝ $87.00OutperformView details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/26/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$422.52
-1.9%
10/21/2026Set Price Target$473.00 ➝ $503.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,386.32
-2.1%
10/21/2026Boost Price Target$1,309.00 ➝ $1,316.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 10/21/2026
Novogen Limited stock logo
KZIA
Novogen
$5.46
+2.7%
10/20/2026Initiated Coverage$30.00OutperformView details for Leerink Partners rating of Novogen (NASDAQ:KZIA) on 10/20/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$579.37
-0.8%
10/19/2026Boost Price Target$685.00 ➝ $725.00OutperformView details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 10/19/2026
TRAX
First Tracks Biotherapeutics
$44.50
+2.1%
10/16/2026Boost Price Target$70.00 ➝ $90.00OutperformView details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 10/16/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$273.66
-1.8%
10/14/2026Lower Price Target$276.00 ➝ $272.00OutperformView details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 10/14/2026
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$8.52
-1.0%
10/14/2026Lower Price Target$14.00 ➝ $10.00Market PerformView details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 10/14/2026
Envista Holdings Corporation stock logo
NVST
Envista
$23.76
+0.3%
10/14/2026Lower Price Target$35.00 ➝ $32.00OutperformView details for Leerink Partners rating of Envista (NYSE:NVST) on 10/14/2026
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$85.60
+3.2%
10/14/2026Set Price Target$96.00 ➝ $92.00Market PerformView details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 10/14/2026
Align Technology, Inc. stock logo
ALGN
Align Technology
$163.72
+0.2%
10/14/2026Lower Price Target$235.00 ➝ $215.00OutperformView details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 10/14/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$0.62
+6.4%
10/12/2026Initiated Coverage$4.00OutperformView details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 10/12/2026
CVS Health Corporation stock logo
CVS
CVS Health
$81.34
-5.2%
10/12/2026Lower Price Target$119.00 ➝ $112.00OutperformView details for Leerink Partners rating of CVS Health (NYSE:CVS) on 10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
$1.08
-11.2%
10/12/2026Initiated Coverage$6.00OutperformView details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$34.75
-3.2%
10/12/2026Initiated Coverage$130.00OutperformView details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 10/12/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$126.80
+1.7%
10/12/2026Initiated Coverage$150.00 ➝ $190.00OutperformView details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 10/12/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$8.58
-0.5%
10/12/2026Initiated Coverage$40.00OutperformView details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 10/12/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$25.66
-2.1%
10/12/2026Initiated Coverage$34.00Market PerformView details for Leerink Partners rating of Vera Therapeutics (NASDAQ:VERA) on 10/12/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.91
-0.8%
10/9/2026Boost Price Target$13.00 ➝ $19.00OutperformView details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$43.68
+1.5%
10/9/2026Lower Price Target$60.00 ➝ $55.00OutperformView details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/9/2026
Stryker Corporation stock logo
SYK
Stryker
$317.76
+0.1%
10/9/2026Lower Price Target$403.00 ➝ $353.00OutperformView details for Leerink Partners rating of Stryker (NYSE:SYK) on 10/9/2026
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$258.30
+0.3%
10/8/2026 Boost Price Target$280.00 ➝ $310.00OutperformView details for Leerink Partners rating of IQVIA (NYSE:IQV) on 10/8/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.33
-3.1%
10/7/2026Downgrade$4.00 ➝ $1.00Outperform ➝ Market PerformView details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026
Cencora, Inc. stock logo
COR
Cencora
$347.61
-0.8%
10/7/2026Boost Price Target$380.00 ➝ $388.00OutperformView details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.33
-3.1%
10/7/2026Downgrade$1.00Outperform ➝ Market PerformView details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026
McKesson Corporation stock logo
MCK
McKesson
$1,081.70
-0.9%
10/7/2026Boost Price Target$1,030.00 ➝ $1,070.00OutperformView details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2026
OmniAb, Inc. stock logo
OABI
OmniAb
$5.07
+0.3%
10/7/2026Boost Price Target$10.00 ➝ $12.00OutperformView details for Leerink Partners rating of OmniAb (NASDAQ:OABI) on 10/7/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.13
+0.7%
10/7/2026Lower Price Target$7.00 ➝ $4.00Market PerformView details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/7/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$59.72
-2.7%
10/5/2026Downgrade$73.00 ➝ $59.00Outperform ➝ Market PerformView details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 10/5/2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$7.65
-4.4%
10/5/2026Initiated Coverage$26.00OutperformView details for Leerink Partners rating of Oric Pharmaceuticals (NASDAQ:ORIC) on 10/5/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$1.39
-6.5%
10/5/2026Initiated Coverage$4.00 ➝ $8.00Market Perform ➝ OutperformView details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 10/5/2026
10x Genomics stock logo
TXG
10x Genomics
$56.51
+0.4%
9/29/2026Boost Price Target$40.00 ➝ $90.00Market PerformView details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$115.77
+3.4%
9/29/2026Boost Price Target$160.00 ➝ $190.00OutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/29/2026
Illumina, Inc. stock logo
ILMN
Illumina
$209.36
+3.3%
9/29/2026Boost Price Target$220.00 ➝ $300.00OutperformView details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 9/29/2026
Bruker Corporation stock logo
BRKR
Bruker
$63.12
+2.9%
9/29/2026Boost Price Target$60.00 ➝ $80.00OutperformView details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 9/29/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$37.51
-1.1%
9/23/2026Boost Price Target$30.00 ➝ $33.00Market PerformView details for Leerink Partners rating of Acadia Healthcare (NASDAQ:ACHC) on 9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$46.46
+1.9%
9/23/2026Lower Price Target$90.00 ➝ $81.00OutperformView details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 9/23/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$27.61
-1.5%
9/23/2026Boost Price Target$70.00 ➝ $88.00OutperformView details for Leerink Partners rating of Celldex Therapeutics (NASDAQ:CLDX) on 9/23/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$3.01
+5.3%
9/23/2026Reiterated Rating$15.00OutperformView details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 9/23/2026
OBX
Obsidian Therapeutics
$12.42
+2.9%
9/22/2026 Initiated Coverage$32.00OutperformView details for Leerink Partners rating of Obsidian Therapeutics (NASDAQ:OBX) on 9/22/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.66
-3.1%
9/21/2026 Boost Price Target$36.00 ➝ $40.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/21/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$538.57
+0.8%
9/21/2026 Initiated Coverage$594.00OutperformView details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/21/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$11.15
-5.0%
9/18/2026Set Price Target$32.00OutperformView details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026
Ardent Health, Inc. stock logo
ARDT
Ardent Health
$14.37
-19.0%
9/18/2026Reiterated Rating$14.00OutperformView details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 9/18/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$11.15
-5.0%
9/18/2026Upgrade$32.00Strong-BuyView details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$3.19
+6.2%
9/18/2026Initiated Coverage$9.00OutperformView details for Leerink Partners rating of Entera Bio (NASDAQ:ENTX) on 9/18/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$473.58
-5.5%
9/18/2026Reiterated Rating$492.00OutperformView details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 9/18/2026
You missed yesterday's deadline… (Ad)

In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel

See which company controls this entire energy discovery now.
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$269.62
-4.4%
9/18/2026Reiterated Rating$309.00OutperformView details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 9/18/2026
Universal Health Services, Inc. stock logo
UHS
Universal Health Services
$186.10
-3.1%
9/18/2026Boost Price Target$198.00 ➝ $205.00OutperformView details for Leerink Partners rating of Universal Health Services (NYSE:UHS) on 9/18/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$115.77
+3.4%
9/17/2026Boost Price Target$120.00 ➝ $160.00OutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/17/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$14.35
-2.5%
9/14/2026Boost Price Target$24.00 ➝ $27.00OutperformView details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 9/14/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.23
+7.9%
9/14/2026Initiated Coverage$13.00OutperformView details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 9/14/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.06
-0.5%
9/14/2026 Initiated Coverage$98.00Hold ➝ OutperformView details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/14/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$119.12
+2.1%
9/14/2026 Initiated Coverage$133.00OutperformView details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 9/14/2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$16.95
+0.9%
9/10/2026Boost Price Target$12.00 ➝ $16.00OutperformView details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 9/10/2026
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
$1.82
-6.4%
9/10/2026Lower Price Target$27.00OutperformView details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.43
-2.6%
9/9/2026Boost Price Target$50.00 ➝ $65.00OutperformView details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026

MarketBeat's community ratings are surveys of what our community members think about Leerink Partners and other research firms in the last 90 days. Vote "Outperform" if you believe Leerink Partners's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Leerink Partners's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
0.0out of 5 (last 90 days)
0 of 5 stars
OUTPERFORM VOTES
0 Believe will outperform the market
UNDERPERFORM VOTES
0 Believe will underperform the market

Leerink Partners' equity research team has issued ratings on 236 companies across 4 sectors over the past 12 months, covered by 22 analysts. The Leerink Partners analysts below are listed by number of ratings issued in the last year.

Leerink Partners Stock Coverage by Sector

Leerink Partners concentrates its research most heavily in Healthcare (95.5%), Industrials (0.4%) and Consumer Discretionary (0.4%). The chart below shows how Leerink Partners' 244 rated companies are distributed across all 4 sectors it covers.

Leerink Partners - Frequently Asked Questions

Leerink Partners' analysts currently have buy-equivalent ratings on 192 companies. Recent upgrades to buy include enGene and Eloxx Pharmaceuticals.

Leerink Partners' highest-rated analysts by MarketBeat's accuracy score include Andrew Berens, Faisal Khurshid and Puneet Souda. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 23 analysts at Leerink Partners.

Leerink Partners has the deepest coverage in Healthcare (95.5% of rated companies), Industrials (0.4% of rated companies), Finance (0.4% of rated companies) and Consumer Discretionary (0.4% of rated companies).

Leerink Partners issued 432 ratings over the last 12 months across 244 companies — an average of roughly 36 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Leerink Partners analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Leerink Partners uses Outperform, Market Perform, and Underperform as their equivalents.